Compare Stocks: IRWD, ABBV, NRIX, and SLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$256.27 -1.5%	$254.66	$190.75 ▼ $267.47	$459.74B	0.29	4.28 million shs	4.73 million shs
IRWD Ironwood Pharmaceuticals	$4.26 -0.7%	$4.18	$1.05 ▼ $5.78	$708.88M	0.2	1.73 million shs	829,289 shs
NRIX Nurix Therapeutics	$26.14 +3.2%	$24.91	$8.19 ▼ $28.23	$2.63B	1.8	1.14 million shs	1.23 million shs
SLS SELLAS Life Sciences Group	$13.86 +1.2%	$12.85	$1.39 ▼ $15.88	$2.77B	2.52	7.23 million shs	4.48 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-1.70%	+0.07%	+4.18%	+12.56%	+21.12%
IRWD Ironwood Pharmaceuticals	-0.70%	+3.15%	+2.65%	+28.70%	+243.55%
NRIX Nurix Therapeutics	+3.24%	-0.27%	+4.06%	+78.55%	+176.32%
SLS SELLAS Life Sciences Group	+1.17%	+4.92%	+16.86%	+68.41%	+678.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$256.27 -1.5%	$254.66	$190.75 ▼ $267.47	$459.74B	0.29	4.28 million shs	4.73 million shs
IRWD Ironwood Pharmaceuticals	$4.26 -0.7%	$4.18	$1.05 ▼ $5.78	$708.88M	0.2	1.73 million shs	829,289 shs
NRIX Nurix Therapeutics	$26.14 +3.2%	$24.91	$8.19 ▼ $28.23	$2.63B	1.8	1.14 million shs	1.23 million shs
SLS SELLAS Life Sciences Group	$13.86 +1.2%	$12.85	$1.39 ▼ $15.88	$2.77B	2.52	7.23 million shs	4.48 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-1.70%	+0.07%	+4.18%	+12.56%	+21.12%
IRWD Ironwood Pharmaceuticals	-0.70%	+3.15%	+2.65%	+28.70%	+243.55%
NRIX Nurix Therapeutics	+3.24%	-0.27%	+4.06%	+78.55%	+176.32%
SLS SELLAS Life Sciences Group	+1.17%	+4.92%	+16.86%	+68.41%	+678.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$275.95	7.68% Upside
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	46.32% Upside
NRIX Nurix Therapeutics	2.80	Moderate Buy	$34.21	30.89% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-27.85% Downside

Current Analyst Ratings Breakdown

Latest IRWD, ABBV, NRIX, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C+)
8/20/2026	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$298.00 ➝ $303.00
8/17/2026	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$295.00 ➝ $300.00
8/13/2026	ABBV AbbVie	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00
8/12/2026	SLS SELLAS Life Sciences Group	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	ABBV AbbVie	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$218.00 ➝ $247.00
8/10/2026	NRIX Nurix Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$33.00 ➝ $36.00
8/7/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/5/2026	ABBV AbbVie	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
8/4/2026	ABBV AbbVie	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Buy (B-)
8/4/2026	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$261.00 ➝ $288.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	7.40	$14.92 per share	17.18	($3.33) per share	-76.96
IRWD Ironwood Pharmaceuticals	$296.15M	2.38	$0.26 per share	16.67	($0.98) per share	-4.35
NRIX Nurix Therapeutics	$83.98M	32.30	N/A	N/A	$5.29 per share	4.94
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.68 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$3.54	72.39	15.87	1.18	9.80%	-422.07%	14.34%	10/30/2026 (Estimated)
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.53	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
NRIX Nurix Therapeutics	-$264.46M	-$3.45	N/A	N/A	N/A	-928.44%	-76.09%	-57.31%	10/8/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)

Latest IRWD, ABBV, NRIX, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
7/31/2026	Q2 2026	ABBV AbbVie	$3.61	$3.65	+$0.04	$2.03	$16.80 billion	$16.99 billion
7/9/2026	Q2 2026	NRIX Nurix Therapeutics	-$0.73	-$0.81	-$0.08	-$0.81	$15.29 million	$9.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	2.70%	+6.80%	195.48%	53 Years
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Latest IRWD, ABBV, NRIX, and SLS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/18/2026	ABBV AbbVie	quarterly	$1.73	2.83%	7/15/2026	7/15/2026	8/14/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.81	0.69
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
NRIX Nurix Therapeutics	N/A	6.34	6.34
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
IRWD Ironwood Pharmaceuticals	N/A
NRIX Nurix Therapeutics	N/A
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
IRWD Ironwood Pharmaceuticals	9.30%
NRIX Nurix Therapeutics	6.70%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
IRWD Ironwood Pharmaceuticals	220	165.24 million	149.87 million	Optionable
NRIX Nurix Therapeutics	300	103.78 million	96.83 million	Optionable
SLS SELLAS Life Sciences Group	10	201.95 million	199.32 million	Not Optionable

IRWD, ABBV, NRIX, and SLS Headlines

Recent News About These Companies

SELLAS Life Sciences Group, Inc. (SLS)

September 4 at 6:42 PM | finance.yahoo.com

Bank of New York Mellon Corp Makes New Investment in SELLAS Life Sciences Group, Inc. $SLS

September 4 at 3:27 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 3 at 10:15 AM | prnewswire.com

SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

September 3 at 2:36 AM | finance.yahoo.com

Most and least shorted mid- to mega-cap healthcare stocks at the end of August

September 2 at 11:34 AM | seekingalpha.com

Sellas gears up to present preclinical SLS009 data for pancreatic cancer at major oncology conference

September 2 at 11:34 AM | msn.com

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

September 2 at 8:30 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 1, 2026 | globenewswire.com

Why analysts think Sellas Life Sciences stock can gain 150% from here

September 1, 2026 | msn.com

Bank of America Corp DE Acquires 540,748 Shares of SELLAS Life Sciences Group, Inc. $SLS

September 1, 2026 | marketbeat.com

Sellas CEO Stergiou says ‘rigorous, unblinded’ data from pivotal AML trial will 'speak for itself' as REGAL catalyst nears

August 31, 2026 | msn.com

SLS stock looks like a $3 billion biotech winner—this short seller says the market has it dangerously wrong: 'Most expensive coin flip' (updated)

August 31, 2026 | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Here's What Happened

August 28, 2026 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 8.8% - Still a Buy?

August 27, 2026 | marketbeat.com

Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline

August 26, 2026 | msn.com

Sellas Life Sciences: A LinkedIn Post Moves the Stock While the Official Filing Stays Silent

August 26, 2026 | ad-hoc-news.deA

SLS traders eye this important resistance zone ahead of key AML data readout

August 24, 2026 | msn.com

SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress

August 24, 2026 | blockonomi.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.4% - Time to Sell?

August 24, 2026 | marketbeat.com

Quantinno Capital Management LP Takes $315,000 Position in SELLAS Life Sciences Group, Inc. $SLS

August 24, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Decibel Cannabis Company (OtherDBCCF) and SELLAS Life Sciences Group (SLS)

August 22, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRWD, ABBV, NRIX, and SLS Company Descriptions

AbbVie NYSE:ABBV

$256.27 -3.94 (-1.51%)

As of 09/4/2026 03:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.26 -0.03 (-0.70%)

As of 09/4/2026 04:00 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Nurix Therapeutics NASDAQ:NRIX

$26.14 +0.82 (+3.24%)

As of 09/4/2026 04:00 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

SELLAS Life Sciences Group NASDAQ:SLS

$13.86 +0.16 (+1.17%)

As of 09/4/2026 04:00 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRWD, ABBV, NRIX, and SLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRWD, ABBV, NRIX, and SLS Earnings

Compare Dividends

Latest IRWD, ABBV, NRIX, and SLS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRWD, ABBV, NRIX, and SLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRWD, ABBV, NRIX, and SLS Company Descriptions

AbbVie NYSE:ABBV

Ironwood Pharmaceuticals NASDAQ:IRWD

Nurix Therapeutics NASDAQ:NRIX

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools